For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
- Second Dose Level in PXS-5505 Myelofibrosis Study Showing Dose Related Increase in Blood Drug Levels and Good Safety Profile in Patients
- Safety Committee Clear Progression to Final Dose
Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on 28 July 2021.
Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 1.00pm AET on Thursday 29 July 2021.
The event will consist of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees.
To register and receive your conference link please click here.
To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to: firstname.lastname@example.orgRead full media release - pdf
- Pharmaxis sells Australian distribution rights for Bronchitol®and Aridol® in Australia, New Zealand and several Asian territories to BTC Health effective July 1st, 2021
- $2m distributor appointment fee to be paid to Pharmaxis
- Streamlining mannitol respiratory business in line with strategy